For patients diagnosed with a malignancy at high risk of developing peritoneal metastases, the concept of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged. The aim of the present study is to assess the role of prophylactic HIPEC in gastric cancer patients at high risk of PC, based on the currently available data in the literature. In total, 14 RCTs and 16 non-RCTs were identified and included in the present review, with 1383 patients included in the RCTs (627 of whom underwent HIPEC) and 1647 patients included in the non-RCTs (with 609 undergoing HIPEC). Prophylactic HIPEC appears to be useful and effective in treating patients with high-risk gastric cancer, improving both overall and disease-free survival. The heterogeneity of data regarding treatment protocols and complication rates suggests that further research is necessary to develop optimal therapeutic approaches and personalized treatment options; in particular, large-scale randomized control trials are needed in order to elucidate the potential benefits associated with the use of prophylactic HIPEC.
对于确诊为恶性肿瘤且腹膜转移高风险的患者，预防性腹腔热灌注化疗（HIPEC）这一概念应运而生。本研究旨在基于现有文献数据，评估预防性HIPEC在高危腹膜转移胃癌患者中的作用。本次综述共纳入14项随机对照试验和16项非随机对照试验，其中随机对照试验包含1383例患者（其中627例接受HIPEC治疗），非随机对照试验包含1647例患者（其中609例接受HIPEC治疗）。预防性HIPEC在治疗高危胃癌患者中显示出有效性和临床价值，能够改善患者的总生存期和无病生存期。关于治疗方案和并发症发生率的数据存在异质性，这表明需要进一步研究以制定最佳治疗策略和个体化治疗方案；特别是需要开展大规模随机对照试验，以阐明预防性HIPEC可能带来的临床获益。
The Role of Prophylactic HIPEC in High-Risk Gastric Cancer Patients: Where Do We Stand?
肿瘤(癌症)患者之家